<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ophthalmol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Ophthalmol Ther</journal-id><journal-title-group><journal-title>Ophthalmology and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8245</issn><issn pub-type="epub">2193-6528</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25786593</article-id><article-id pub-id-type="pmc">4470983</article-id><article-id pub-id-type="publisher-id">29</article-id><article-id pub-id-type="doi">10.1007/s40123-015-0029-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Comment on: &#x0201c;Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population&#x0201d;</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hall</surname><given-names>John</given-names></name><address><email>John.Hall@alimerasciences.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Alimera Sciences, Guildford, UK </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2015</year></pub-date><volume>4</volume><issue>1</issue><fpage>65</fpage><lpage>66</lpage><history><date date-type="received"><day>12</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>I read &#x0201c;Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis (NIPU): 3-year results of a randomized clinical trial in a predominantly Asian population&#x0201d; (December 2014) [<xref ref-type="bibr" rid="CR1">1</xref>]. This article is certainly of interest, especially regarding the effectiveness of 0.59 and 2.1&#x000a0;mg doses of fluocinolone acetonide (FAc) intravitreal implant for the treatment of NIPU in a predominantly Asian patient population.</p><p>However, I would like to make sure that your readership does not confuse the FAc intravitreal implant reported by Sangwanet al. (i.e., Retisert; contains 0.59&#x000a0;mg of FAc) with the FAc implant (ILUVIEN<sup>&#x000ae;</sup>; contains 190&#x000a0;&#x003bc;g of FAc) licenced in Europe for the indication &#x02018;&#x02026; for the treatment of vision impairment associated with chronic diabetic macular edema (DMO), considered insufficiently responsive to available therapies [<xref ref-type="bibr" rid="CR2">2</xref>]&#x02019;. This letter highlights the key differences between Retisert and ILUVIEN.</p><p><italic>These products are licenced by different manufacturers</italic>. Retisert is manufactured by Bausch &#x00026; Lomb (Rochester, NY, USA) and ILUVIEN is manufactured by Alimera Sciences (based in Atlanta, Georgia, USA and Aldershot, UK).</p><p><italic>These products contain and deliver different amounts of FAc</italic>. Retisert delivers 0.59&#x000a0;mg of FAc with an initial rate of 0.6&#x000a0;mg of FAc per day, which decreases over the 1st month to a steady rate of 0.3&#x02013;0.4&#x000a0;&#x003bc;g FAc per day [<xref ref-type="bibr" rid="CR3">3</xref>]. ILUVIEN contains a total of 190&#x000a0;&#x003bc;g of FAc with an average daily release of 0.2&#x000a0;&#x003bc;g of FAc per day [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p><italic>These products release FAc for different amounts of time.</italic> Retisert releases 0.3&#x02013;0.4&#x000a0;&#x003bc;g FAc per day for between 30 [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>] and 36&#x000a0;months [<xref ref-type="bibr" rid="CR1">1</xref>]. In contrast, ILUVIEN releases 0.2&#x000a0;&#x003bc;g FAc per day for up to 36&#x000a0;months [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p><italic>These products are administered differently.</italic> Retisert is surgically implanted into the posterior segment of the affected eye through a pars plana incision. ILUVIEN is an intravitreal implant that is inserted using a 25-gage needle into the vitreous cavity in the posterior eye with the optimal placement being inferior to the optic disc and posterior to the equator [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p><italic>These products have different indications</italic>. In Europe, Retisert is not licensed whereas ILUVIEN is licensed and indicated for &#x0201c;&#x02026; the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.&#x0201d; [<xref ref-type="bibr" rid="CR2">2</xref>]. In the USA, Retisert is indicated for &#x0201c;&#x02026;the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye&#x0201d; [<xref ref-type="bibr" rid="CR3">3</xref>] and not for DMO. The indication for ILUVIEN in the USA is for &#x0201c;&#x02026;or the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure&#x0201d; [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>I would like to highlight that ILUVIEN was designed to improve on the performance of Retisert to deliver the lowest dose of corticosteroid, currently under investigation, to the retina [<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, I would like to point the reader in the direction of Kane et al. [<xref ref-type="bibr" rid="CR6">6</xref>] which explains the development history and characteristics of Retisert and ILUVIEN. The paper by Campochiaro et al. [<xref ref-type="bibr" rid="CR4">4</xref>] is also very helpful as it compares the aqueous levels of FAc after the administration of Retisert or ILUVIEN.</p><p>John Hall, MD</p><p>Senior Vice President,</p><p>Medical Director Europe</p></body><back><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Sangwan VS, Pearson PA, Paul H, Comstock TL. Use of the fluocinolone acetonide the intravitreal implant for treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population. Ophthalmol Ther. 2014 (Epub ahead of print). Source: <ext-link ext-link-type="uri" xlink:href="http://link.springer.com/article/10.1007/s40123-014-0027-6">http://link.springer.com/article/10.1007/s40123-014-0027-6</ext-link>. Accessed: 12 Feb 2015.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Summary of Product Characteristics for ILUVIEN 190 micrograms intravitreal implant in applicator. Source: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/medicine/27636">https://www.medicines.org.uk/emc/medicine/27636</ext-link>. Accessed: 12 Feb 2015.</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Retisert Prescribing Information. Source: <ext-link ext-link-type="uri" xlink:href="http://www.bausch.com/Portals/107/-/m/BL/United%20States/USFiles/Package%20Inserts/Pharma/retisert-prescribing-information.pdf">http://www.bausch.com/Portals/107/-/m/BL/United%20States/USFiles/Package%20Inserts/Pharma/retisert-prescribing-information.pdf</ext-link>. Accessed: 12 Feb 2015.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campochiaro</surname><given-names>PA</given-names></name><name><surname>Nguyen</surname><given-names>QD</given-names></name><name><surname>Hafiz</surname><given-names>G</given-names></name><name><surname>Bloom</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Busquets</surname><given-names>M</given-names></name><name><surname>Ciulla</surname><given-names>T</given-names></name><name><surname>Feiner</surname><given-names>L</given-names></name><name><surname>Sabates</surname><given-names>N</given-names></name><name><surname>Billman</surname><given-names>K</given-names></name><name><surname>Kapik</surname><given-names>B</given-names></name><name><surname>Green</surname><given-names>K</given-names></name><name><surname>Kane</surname><given-names>FE</given-names></name><collab>FAMOUS Study Group</collab></person-group><article-title>Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants</article-title><source>Ophthalmology</source><year>2013</year><volume>120</volume><issue>3</issue><fpage>583</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2012.09.014</pub-id><pub-id pub-id-type="pmid">23218184</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">New Drug Application for ILUVIEN (fluocinolone acetonide intravitreal insert). Reference NDA 201923. Source: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/201923Orig1s000ltr.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/201923Orig1s000ltr.pdf</ext-link>. Accessed: 12 Mar 2015.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kane</surname><given-names>FE</given-names></name><name><surname>Burdan</surname><given-names>J</given-names></name><name><surname>Cutino</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>KE</given-names></name></person-group><article-title>ILUVIEN: a new sustained delivery technology for posterior eye disease</article-title><source>Expert Opin Drug Deliv</source><year>2008</year><volume>5</volume><issue>9</issue><fpage>1039</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1517/17425247.5.9.1039</pub-id><pub-id pub-id-type="pmid">18754752</pub-id></element-citation></ref></ref-list></back></article>